stock offering
Candel Therapeutics to Raise $80M in Public Stock and Warrants Offering
The firm plans to put the funds toward a biologics licensing application for its lead product candidate CAN-2409 in prostate cancer.
Immatics Prices $150M Stock Offering
The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.
Immatics to Raise $150M in Public Stock Offering
The firm is developing T-cell receptor therapies for advanced solid tumors including metastatic melanoma.
Ionis Pharmaceuticals Prices $500.3M Stock Offering
The antisense oligonucleotide developer plans to use the funds raised to support its independent commercial launches, late-stage clinical programs, and more.
Precigen Announces Strategic Reprioritization, $30M Public Offering
The reprioritization and offering will allow the firm to focus on commercializing its investigational gene therapy for recurrent respiratory papillomatosis.
Jun 21, 2024
Angle Raises $630K in Open Offer of Shares
Mar 22, 2024
Sangamo Prices $24M Direct Offering of Common Stock
Feb 1, 2024
Evaxion Biotech Prices $15M Public Offering
Jan 18, 2024
Immatics to Raise $175M in Public Stock Offering
Dec 15, 2023
Syndax Pharmaceuticals Prices $200M Stock Offering
Oct 16, 2023
Nuvalent Announces $300M Public Stock Offering
Jun 15, 2023